Latest filings (excl ownership)
PX14A6G
Letter to shareholders
26 Mar 24
ARS
2023 FY
Annual report to shareholders
18 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
8-K
Other Events
26 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
FWP
Free writing prospectus
22 Feb 24
S-8
Registration of securities for employees
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
20 Feb 24
8-K
AbbVie Completes Acquisition of ImmunoGen
12 Feb 24
8-K
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2 Feb 24
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
5 Jan 24
8-K
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
6 Dec 23
8-K
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
30 Nov 23
25-NSE
Exchange delisting
15 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
AbbVie Reports Third-Quarter 2023 Financial Results
27 Oct 23
8-K
Departure of Directors or Certain Officers
12 Oct 23
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4 Oct 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
AbbVie Reports Second-Quarter 2023 Financial Results
27 Jul 23
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
6 Jul 23
8-K
Departure of Directors or Certain Officers
29 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jun 23
SD
Conflict minerals disclosure
31 May 23
8-K
Submission of Matters to a Vote of Security Holders
10 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
PX14A6G
Letter to shareholders
4 May 23
8-K
AbbVie Reports First-Quarter 2023 Financial Results
27 Apr 23
PX14A6G
Letter to shareholders
20 Apr 23
PX14A6G
Letter to shareholders
11 Apr 23
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
5 Apr 23
8-K
Entry into a Material Definitive Agreement
28 Mar 23
DEFA14A
Additional proxy soliciting materials
28 Mar 23
PX14A6G
Letter to shareholders
28 Mar 23
PX14A6G
Letter to shareholders
27 Mar 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
Latest ownership filings
4
Nicholas Donoghoe
22 Mar 24
144/A
Notice of proposed sale of securities (amended)
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Jeffrey Ryan Stewart
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
TIMOTHY J. RICHMOND
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Scott T Reents
1 Mar 24
4
Kevin K Buckbee
1 Mar 24
4
Robert A. Michael
1 Mar 24
4
Perry C Siatis
1 Mar 24
4
Jeffrey Ryan Stewart
1 Mar 24
4
AZITA SALEKI-GERHARDT
1 Mar 24
4
TIMOTHY J. RICHMOND
1 Mar 24
4
Thomas J Hudson
1 Mar 24
4
Roopal Thakkar
1 Mar 24
4
Nicholas Donoghoe
1 Mar 24
4
RICHARD A GONZALEZ
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
4
RICHARD A GONZALEZ
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
4
Perry C Siatis
27 Feb 24
4
AZITA SALEKI-GERHARDT
23 Feb 24
144
Notice of proposed sale of securities
23 Feb 24
144
Notice of proposed sale of securities
21 Feb 24
4
AZITA SALEKI-GERHARDT
20 Feb 24
4
TIMOTHY J. RICHMOND
20 Feb 24
4
Nicholas Donoghoe
20 Feb 24
4
Kevin K Buckbee
20 Feb 24
4
Roopal Thakkar
20 Feb 24
4
Perry C Siatis
20 Feb 24
4
Scott T Reents
20 Feb 24
4
Thomas J Hudson
20 Feb 24
4
Jeffrey Ryan Stewart
20 Feb 24
4
Robert A. Michael
20 Feb 24
4
RICHARD A GONZALEZ
20 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24